Indapta Therapeutics

About Indapta Therapeutics

Indapta Therapeutics is a biotechnology company focused on developing and commercializing a proprietary, off-the-shelf, allogeneic FcRγ-deficient natural killer (G-NK) cell therapy to treat cancer and autoimmune diseases. Based in Houston, TX, and Seattle, WA, the company harnesses the natural power of the immune system with its universal NK cell platform derived from healthy donors to address limitations of current therapies.

Products & Services

G-NK Cell Therapy (IDP-023):An allogeneic, off-the-shelf natural killer (NK) cell therapy deficient in the FceR1γ protein, designed to treat multiple types of cancer and autoimmune diseases like multiple sclerosis. It shows enhanced cytotoxicity, persistence, and efficacy when combined with FDA-approved tumor-targeting antibodies such as rituximab and daratumumab.

Specialties

Allogeneic Natural Killer (NK) Cell Therapy G-NK Cell Platform Cancer Immunotherapy Autoimmune Disease Treatment Off-the-shelf Cellular Therapies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: New financing round T: - FT: New financing round	A: 22500000 MR: - FA: 22.5 million FAN: 22500000	D: 2024-12-17 FD: 2024-12-17	5 investors
2	RT: Grant T: - FT: Grant	A: 4500000 MR: - FA: $4.5 million FAN: 4500000	D: 2024-05-21 FD: 2024-05-21	1 investors

New financing round Latest

2024-12-17

$22.5M

5 investors (Pro only)

Grant 2024-05-21

$4.5M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Mark W. Frohlich

Chief Executive Officer

LinkedIn (Pro only)

G

Guy DiPierro

Chief Operating Officer & Co-Founder

A

Austin Bigley

VP of Manufacturing Science & Technology

L

Linda Barnes

Head of Regulatory & Quality

A

Andrei Shustov

Head of Clinical Development

S

Stefanie Mandl-Cashman

Acting Chief Scientific Officer

View 15 more team members with Pro

Unlock Full Team Directory

Recent News